Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.73|
|52 Week High||US$3.15|
|52 Week Low||US$8.78|
|1 Month Change||-11.71%|
|3 Month Change||54.86%|
|1 Year Change||-22.98%|
|3 Year Change||239.05%|
|5 Year Change||282.00%|
|Change since IPO||-8.32%|
Recent News & Updates
|DYAI||US Biotechs||US Market|
Return vs Industry: DYAI underperformed the US Biotechs industry which returned 26% over the past year.
Return vs Market: DYAI underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: DYAI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: DYAI's weekly volatility has increased from 13% to 18% over the past year.
About the Company
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.
Dyadic International Fundamentals Summary
|DYAI fundamental statistics|
Is DYAI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DYAI income statement (TTM)|
|Cost of Revenue||US$1.74m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.41|
|Net Profit Margin||-537.10%|
How did DYAI perform over the long term?See historical performance and comparison
Is Dyadic International undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DYAI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DYAI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DYAI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: DYAI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DYAI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DYAI is overvalued based on its PB Ratio (6.9x) compared to the US Biotechs industry average (3.3x).
How is Dyadic International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DYAI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DYAI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DYAI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DYAI's revenue (21.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: DYAI's revenue (21.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DYAI's Return on Equity is forecast to be high in 3 years time
How has Dyadic International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DYAI is currently unprofitable.
Growing Profit Margin: DYAI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DYAI is unprofitable, and losses have increased over the past 5 years at a rate of 34.3% per year.
Accelerating Growth: Unable to compare DYAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DYAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: DYAI has a negative Return on Equity (-50.09%), as it is currently unprofitable.
How is Dyadic International's financial position?
Financial Position Analysis
Short Term Liabilities: DYAI's short term assets ($26.2M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: DYAI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DYAI is debt free.
Reducing Debt: DYAI had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DYAI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DYAI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.9% each year
What is Dyadic International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DYAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DYAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DYAI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DYAI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DYAI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Emalfarb (65 yo)
Mr. Mark A. Emalfarb Founded Dyadic International Inc., in 1979 and has been its Chief Executive Officer since October 2004. Mr. Emalfarb has been the President of Dyadic International Inc., since October...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD1.38M) is about average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Experienced Management: DYAI's management team is seasoned and experienced (6.1 years average tenure).
Experienced Board: DYAI's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DYAI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Dyadic International, Inc.'s employee growth, exchange listings and data sources
- Name: Dyadic International, Inc.
- Ticker: DYAI
- Exchange: NasdaqCM
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$160.894m
- Shares outstanding: 28.08m
- Website: https://www.dyadic.com
Number of Employees
- Dyadic International, Inc.
- 140 Intracoastal Pointe Drive
- Suite 404
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 22:07|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.